DVA DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.…
Industry Peers
Medical Care FacilitiesKey Statistics
About DaVita (NYSE: DVA)
›
DaVita (NYSE: DVA) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Care Facilities industry, part of the Healthcare sector, and reports about 78,000 employees.
The shares were at 156.34 USD on 19 November 2026, up 28.6% over 52 weeks. Its 52-week range is 101.00 USD to 247.49 USD: the price is 36.8% below the high and 54.8% above the low.
At a market capitalisation of 9.83B USD, it trades at 11.8 times trailing earnings and 9.2 times forward earnings. The median trailing P/E of its 18 largest Medical Care Facilities peers is 23.7, a discount of 50% for DVA.
DaVita reports return on equity of -114.7%, an operating margin of 15.2% and revenue up 4.6% year over year.
Its debt exceeds its cash by 12.83B USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 7 analysts cover the stock, with an average rating of Hold; their mean price target of 222.29 USD is 42.2% above the current price. The next earnings report is expected on 1 February 2027.